推荐产品
生化/生理作用
Gardiquimod是一种新型咪唑并喹啉化合物。它在表达了人或鼠toll样受体7（TLR7）的细胞中可刺激NF-κB（核因子-κB）的活化。Gardiquimod的效率是咪喹莫特的十倍。它可诱导脾细胞活化并防止鼠B16黑色素瘤生长和转移。Gardiquimod可作为预防HIV-1（人类免疫缺陷病毒-1）传播的一种治疗剂。它可通过阻止HIV-1逆转录酶的作用而对HIV-1的生命周期进行阻遏。
Gardiquimod是人或小鼠Toll样受体7（TLR7）的一种有效的特异性激动剂。同样，高浓度的gardiquimod会激活TLR8。与咪喹莫特相似，gardiquimod可以模拟病毒核酸对免疫系统的影响。
特点和优势
《受体分类和信号转导》手册的 细胞因子受体（白细胞介素-1受体/TIR家族） 页面有该化合物的介绍。想要浏览手册的其他页面， 请单击此处。
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
从最新的版本中选择一种：
分析证书(COA)
Lot/Batch Number
The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
Ma F, et al.
Cellular & Molecular Immunology, 7(5), 381-381 (2010)
Maarten Buitendijk et al.
AIDS research and human retroviruses, 29(6), 907-918 (2013-01-16)
Immune response modifiers are being studied as therapeutic agents for viral infections and cancer. These molecules include agonists for the Toll-like receptors (TLR), a family of innate immune receptors. TLR7 and 8, located in cellular endosomes, bind single-stranded RNA characteristic
Rosmely Hernandez et al.
Journal for immunotherapy of cancer, 9(9) (2021-09-04)
Immunization with tumor neoantigens is a promising vaccine approach to promote antitumor immunity due to their high immunogenicity, lack of expression in normal tissue, and preferential induction of tumor neoantigen-specific T cells, which are central mediators of the anti-cancer response.
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门